Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006576 · ClinicalTrials.gov registry record · Phase 2
Prostaglandin Inhibition for Emphysema
A Phase 2 study of Emphysema, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 5
- Study locations
NCT02006576 is a Phase 2 study of Emphysema that has completed, run by University of Nebraska. The registered enrollment target is 118 participants, below the 3,799-participant average among 25 other Emphysema trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT02006576, a Phase 2 study of Emphysema, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in improvement in measures of lung repair function.
Conditions Studied
Interventions
- DRUG 600 mg ibuprofen three times daily for 48 weeks
- OTHER Placebo three times daily
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Harbor-UCLA Medical Center - Torrance
Colorado
- National Jewish Health - Denver
Nebraska
- Univerisity of Nebraska Medical Center - Omaha
Pennsylvania
- Temple University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2014-01-01 |
| Est. Completion | 2018-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02006576
The ClinicalTrials.gov registry entry for NCT02006576 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,799-participant average among 25 other Emphysema trials with a reported enrollment target (97% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Emphysema appearing as the primary indexed condition, and to 2 interventions - of which 600 mg ibuprofen three times daily for 48 weeks is the first listed.
NCT02006576 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02006576 about?
NCT02006576 is a clinical study titled "Prostaglandin Inhibition for Emphysema". The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in improvement in measures of lung repair function.
What is the current status of trial NCT02006576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2014-01-01. Estimated completion is 2018-03-31.
What conditions does trial NCT02006576 study?
This clinical trial studies the following conditions: Emphysema.
What interventions are being tested in trial NCT02006576?
The interventions under investigation include: 600 mg ibuprofen three times daily for 48 weeks (DRUG), Placebo three times daily (OTHER).
Who is sponsoring clinical trial NCT02006576?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02006576 being conducted?
This trial has 5 study locations across Alabama, California, Colorado, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Emphysema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies
COMPLETED · Phase 2
-
COPD Patient-Powered Research Network
RECRUITING
-
Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.